Advertisement


Claudio Cerchione, MD, PhD, on Staging Multiple Myeloma: New Findings on FDG PET/CT Scans and Whole-Body MRI

2024 ASCO Annual Meeting

Advertisement

Claudio Cerchione, MD, PhD, of Italy’s Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori, discusses preliminary findings from a prospective trial suggesting that by adding whole-body MRI to fludeoxyglucose-18 (FDG) PET/CT scans, clinicians may detect bone lesions earlier and more accurately in patients with either newly diagnosed or relapsed multiple myeloma, thus translating into potentially better outcomes (Abstract 7512).



Transcript

Disclaimer: This video transcript has not been proofread or edited and may contain errors.
In [the] last year, we have seen a great therapeutic revolution in multiple myeloma, according to many new drugs and new combination that have been approved and registered. However, I think that we should also concentrate and optimize the use of therapeutic solution and of novelties that we have seen in last years, thanks to the concentration on diagnostic tools. In this institution that we have realized, in my cancer center, we have seen the combination between whole body MRI, together with the PET FDG, which is the standard of care worldwide, both in patient newly diagnosed in relapsed refractory. And we have checked these diagnostic tools, is smoldering myeloma, as you can see in another poster presentation. Also, a task for 2024. We have seen that the combination of the double technique can totally change the journey of our patient, particularly thanks to the accuracy of whole body MRI, that is of about 97 as we have seen. And we have studied 73 patients, both newly diagnosed in the relapsed refractory. In which we have seen that in 26% of them, the combination of techniques can change their journey, particularly changing the potential treatment that we can anticipate before that signs and symptoms arise. And I think that this is particularly important because we can start to treat the patient before that he is going to suffer for myeloma pains. In particular, the combination of whole body MRI together with FDG-PET, can better characterize the bone lesion that are the main characteristic for which we treat the patient in multiple diagnosis and relapse and refractory setting. And this was the first part of the study, the radiomic part that we have presented here. But we are going to, in some way, potentiate to the study, adding a biologic characterization of our patient, in which we want to develop new biomarkers' evaluation, in the idea of having a biomarkers driven approach in next future studying metabolomic pathways. In order to start maybe to think to a dream, the personalized medicine in multiple myeloma. Which thanks to this multiomic study, we can better characterize, thanks to new generation tools our patient, and really optimize the exact drug for every patient. I think that the time is mature to concentrate on also a new prognostic score in multiple myeloma because we have seen a changing over the treatment, both in newly [inaudible 00:02:40] and the relapsed refractory setting. But we should now concentrate in changing the prognostic index that is of many years ago. This is the way to optimize all what we offer to our patient. Not only in terms of treatment, but also in terms of lifetime expectancy. And thanks to biological characterization that we are performing inside this study, we dream also to think about an MRD evaluation that could take to maybe a treatment-free remission or to optimize the dosing, dose dense and dose intensity of the drug, imagining to in some way have the patient not in ongoing treatment. And this is what they want. However, I think that the optimization of diagnostic tools can be in some way something that will help us to run toward the cure in multiple myeloma. That is not so far, and this is the best wish that we give to our patients, to their caregivers, and to all myeloma researchers around the world.

Related Videos

Gynecologic Cancers

Katherine C. Fuh, MD, PhD, on Ovarian Cancer: New Data on Batiraxcept and Paclitaxel

Katherine C. Fuh, MD, PhD, of the University of California, San Francisco, discusses phase III findings of the AXLerate-OC trial, showing that batiraxcept with paclitaxel compared to paclitaxel alone improved progression-free and overall survival in patients with platinum-resistant recurrent ovarian cancer whose tumors were AXL-high in an exploratory analysis (LBA5515).

Lymphoma

David J. Andorsky, MD, on DLBCL and FL: New Data on Use of Subcutaneous Epcoritamab

David J. Andorsky, MD, of the Sarah Cannon Research Institute and Rocky Mountain Cancer Centers, discusses EPCORE NHL-6, an ongoing study of patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma (FL). As outpatients, the study participants were given subcutaneous epcoritamab-bysp to see whether they could be safely monitored and cytokine-release syndrome appropriately managed in the outpatient setting (Abstract 7029).

Multiple Myeloma

Thierry Facon, MD, on Multiple Myeloma: Results From the IMROZ Study on Isatuximab, Bortezomib, Lenalidomide, and Dexamethasone

Thierry Facon, MD, of the University of Lille and Lille University Hospital, discusses phase III findings showing for the first time that isatuximab, an anti-CD38 monoclonal antibody, when given with the standard of care (bortezomib, lenalidomide, dexamethasone, or VRd) to patients with newly diagnosed multiple myeloma who are transplant-ineligible, may reduce the risk of disease progression or death by 40.4% vs VRd alone (Abstract 7500).

Lymphoma

Yasmin H. Karimi, MD, on Large B-Cell Lymphoma: Follow-up on Subcutaneous Epcoritamab Monotherapy

Yasmin H. Karimi, MD, of the University of Michigan Comprehensive Cancer Center, discusses 2.5-year follow-up data on epcoritamab monotherapy for patients with relapsed or refractory large B-cell lymphoma. The subcutaneous regimen continues to demonstrate durable responses (Abstract 7039).

Kidney Cancer

Toni K. Choueiri, MD, FASCO, on RCC: Biomarker Analysis From the CLEAR Trial

Toni K. Choueiri, MD, FASCO, of the Dana-Farber Cancer Institute, discusses phase III findings showing that, in patients with advanced renal cell carcinoma (RCC), the benefit of lenvatinib plus pembrolizumab vs sunitinib in overall response rate does not appear to be affected by such factors as geneexpression signatures for tumorinduced proliferation, PDL1 status, or the mutation status of RCC driver genes.

Advertisement

Advertisement




Advertisement